GALDERMA
5.1.2022 09:02:07 CET | Business Wire | Press release
Galderma, the world’s largest independent dermatology company, announced today that it has received antitrust clearance from the U.S. authorities and has completed the acquisition of ALASTIN Skincare® , Inc. (“ALASTIN”), a specialty aesthetics company dedicated to developing innovative and clinically-tested physician-dispensed skincare products. The transaction was previously announced on November 29, 2021.
“I am so happy to officially welcome the ALASTIN team to Galderma. As a part of our integrated dermatology approach, we are continuously seeking to add products that synergize with our premium portfolio - and ALASTIN is the perfect fit.
The ALASTIN brand’s proprietary and award-winning skincare technology, combined with Galderma’s world-class pipeline and innovation track record, represents an unparalleled opportunity for Galderma to better meet the needs of aesthetic professionals and patients, now and well into the future.”
FLEMMING ØRNSKOV, M.D., MPH CHIEF EXECUTIVE OFFICER GALDERMA |
Galderma has consistently delivered strong results and remains at the forefront of the rapidly expanding global skincare market. Consumer interest in and acceptance of aesthetic procedures is increasing rapidly, and the addition of ALASTIN’s synergistic portfolio and expertise in science-based skincare will increase Galderma’s ability to serve the needs of both consumers and professionals. ALASTIN’s product offerings are backed by the patented TriHex Technology® , a proprietary blend of peptides and active botanicals to support the appearance of rejuvenated skin.
ALASTIN’s performance has been marked by rapid and constant sales growth, and in 2020 it was named the fastest-growing brand in the professional skincare market in the U.S. This acquisition will enhance Galderma’s integrated dermatology platform with a comprehensive collection of scientifically-proven products for daily skincare regimens and peri-procedural use, and underscores the company’s commitment to be the partner of choice for aesthetic professionals.
“Our team is extremely excited to be joining the Galderma family, and our shared focus on customers and commitment to driving innovation means we’re a winning combination. Galderma’s global reach and cutting-edge research and development platform will help deliver ALASTIN’s next growth phase and support further innovation of ALASTIN’s products.”
DIANE S. GOOSTREE PRESIDENT AND CEO ALASTIN SKINCARE
|
Ropes & Gray LLP acted as legal advisor to Galderma, and Latham & Watkins LLP acted as legal advisor to ALASTIN. William Blair & Company, LLC served as the exclusive financial advisor to ALASTIN.
About Galderma
Galderma is the world’s largest independent dermatology company, present in approximately 100 countries. Since our inception in 1981, we have been driven by a complete dedication to dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Aesthetics, Consumer Care and Prescription Medicine. Focused on the needs of consumers and patients, we work in partnership with healthcare professionals to ensure superior outcomes. Because we understand that the skin we’re in shapes our life stories, we are advancing dermatology for every skin story. For more information: www.galderma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220105005072/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabVantage Named a Visionary Leader in Life Sciences and Industrial LIMS by Frost & Sullivan21.9.2026 10:30:00 CEST | Press release
— Dual recognition in 2026 Frost Radar™ reports marks a fourth consecutive year of Frost Radar leadership — — Frost & Sullivan cited LabVantage CORTEX™ (for life sciences) and LIMS deployments spanning food and beverage, oil and gas, forensics, and government laboratories (for other industrial applications) — LabVantage Solutions, Inc., a leading global provider of laboratory informatics solutions and services, has been named a Visionary Leader in two 2026 Frost Radar™ reports by Frost & Sullivan: Frost Radar™: Life Sciences Laboratory Information Management Systems, 2026 and Frost Radar™: Laboratory Information Management Systems in Industrial Applications, 2026. Announced at LabVantage’s Customer Training and Education Conference (CTEC) Europe 2026 in Paris, the dual recognition marks LabVantage’s fourth consecutive year of Frost Radar leadership. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260921487430/en/ The Frost Ra
Bending Spoons opens office in Warsaw as Polish applications reach 50,000 in 202621.9.2026 09:15:00 CEST | Press release
Bending Spoons has opened an office in Warsaw, adding to its Milan headquarters and locations in London and Madrid. The technology company, whose portfolio includes Eventbrite and WeTransfer, has seen a sharp rise in applications from Poland and will use the new base to recruit locally for roles across key projects. “We’ve received around 50,000 applications from Poland so far this year, more than twice as many as the whole of 2025. What stands out isn’t just the volume. Many Polish candidates are among the strongest we see in our selection process, and the student talent has been particularly impressive. More than half of our recent hires from Poland were still studying when they applied,” says Andrea Maiorana, Talent data lead. Located in Śródmieście, Warsaw’s city center, the office is within walking distance of the Presidential Palace and the University of Warsaw. Bending Spoons encourages all new hires to spend their first few months in Milan, with travel and accommodation costs f
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom